Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Relay Therapeutics reports promising early results for its experimental drug RLY-2608 in treating hard-to-treat breast cancers, showing tumor shrinkage and a good safety profile.

flag Relay Therapeutics reports early positive results from a trial of its experimental drug RLY-2608 in treating difficult-to-treat breast cancers, including triple-negative and hormone receptor-positive types. flag The drug, which targets a protein linked to cancer growth, caused significant tumor shrinkage in some patients, with partial or complete responses observed. flag Presented at a medical conference, the findings highlight RLY-2608’s potential as a new treatment option for patients who have exhausted standard therapies, along with a favorable safety profile in early testing. flag While still in early development, the data have sparked optimism, prompting Relay to advance the drug into larger trials. flag Further research is needed to confirm long-term effectiveness and safety.

3 Articles